UNDERSTANDING THE PATHWAY

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma

  • Arunachalam, Arun Kumar MD1
  • Gilmour, Cassandra K. PhD1
  • Melenhorst, Jan Joseph PhD1,,

  • 1

    Cell Therapy & Immuno-Engineering Program, Cancer Sciences & Translational Oncology, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH
Jan Joseph Melenhorst, PhD; e-mail: [email protected].
Journal of Clinical Oncology 43(20):p 2296-2299, July 10, 2025. | DOI: 10.1200/JCO-25-00568

Corresponding Article

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma

  • Shah, Nirav N. MD, MS1,,
  • Colina, Alfredo S. BA2
  • Johnson, Bryon D. PhD1,
  • Szabo, Aniko PhD3
  • Furqan, Fateeha MD1
  • Kearl, Tyce MD, PhD1
  • Schneider, Dina PhD4,
  • Vargas-Cortes, Marlenny BS5
  • Schmeling, Jessica L. BS5
  • Dwinell, Michael B. PhD2,
  • Palen, Katie BS1
  • Longo, Walter MD1
  • Hematti, Peiman MD1,
  • Zamora, Anthony E. PhD2,
  • Hari, Parameswaran MD, MS1,
  • Bucklan, Daniel MD6
  • Cunningham, Ashley MD7
  • Hamadani, Mehdi MD1,
  • Fenske, Timothy S. MD1,
Journal of Clinical Oncology 43(20):p 2285-2295, July 10, 2025. | DOI: 10.1200/JCO-24-02158
Copyright © 2025 by American Society of Clinical Oncology